vTv’s azeliragon study for Alzheimer’s disease and type 2 diabetes has support but some scepticism remains

shutterstock_606705356
vTv Therapeutics’ azeliragon could have an improved chance of success in an ongoing Phase II and planned Phase III for patients with AD and type 2 diabetes. Credit: Maya Kruchankova via Shutterstock.